[go: up one dir, main page]

MX2019001084A - Variantes de gpr156 y usos de estas. - Google Patents

Variantes de gpr156 y usos de estas.

Info

Publication number
MX2019001084A
MX2019001084A MX2019001084A MX2019001084A MX2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A
Authority
MX
Mexico
Prior art keywords
gpr156
aspartic acid
disclosure
protein
alterations
Prior art date
Application number
MX2019001084A
Other languages
English (en)
Inventor
Gonzaga-Jauregui Claudia
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019001084A publication Critical patent/MX2019001084A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción proporciona ácidos nucleicos, incluso ADNc, que comprenden alteraciones que codifican ácido aspártico en una posición correspondiente a la posición 533 de la proteína del receptor 156 acoplado a la proteína G (GPR156) de humano. La descripción también proporciona variantes de proteína GPR156 de humano recombinantes y aisladas que comprenden un ácido aspártico en una posición correspondiente a la posición 533. El cambio en el ácido aspártico, y el gen que codifica este cambio, se asocian con la depresión unipolar. La descripción también proporciona métodos para determinar si un sujeto padece o está en riesgo de desarrollar depresión unipolar, en función de la identificación de dichas alteraciones en el gen (ADN o ARN) que codifica GPR156.
MX2019001084A 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas. MX2019001084A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (1)

Publication Number Publication Date
MX2019001084A true MX2019001084A (es) 2019-06-10

Family

ID=59649989

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001084A MX2019001084A (es) 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas.
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Country Status (13)

Country Link
US (4) US10266582B2 (es)
EP (2) EP3491014B1 (es)
JP (2) JP7556688B2 (es)
KR (2) KR20240027874A (es)
CN (1) CN109563516B (es)
AU (1) AU2017302611B2 (es)
CA (1) CA3032124A1 (es)
DK (1) DK3491014T5 (es)
IL (1) IL264473A (es)
MX (2) MX2019001084A (es)
NZ (1) NZ751010A (es)
SG (1) SG11201900738YA (es)
WO (1) WO2018022967A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027874A (ko) 2016-07-28 2024-03-04 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도
AU2018328120B2 (en) 2017-09-06 2024-11-14 Regeneron Pharmaceuticals, Inc. Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) variants and uses thereof
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US11470828B2 (en) 2019-01-17 2022-10-18 Regeneran Pharmaceuticals, Inc. Rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
AU3222795A (en) 1994-08-09 1996-03-07 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
JP2000506384A (ja) 1996-02-15 2000-05-30 ナショナル インスティチューツ オブ ヘルス RNase L アクチベーター及びRSV感染の治療に有効なアンチセンスオリゴヌクレオチド
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2001079230A2 (en) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Gタンパク質共役受容体およびその使用
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
WO2008061209A2 (en) 2006-11-15 2008-05-22 Omeros Corporation G protein coupled receptors and uses thereof
JP2015518712A (ja) * 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Mecp2発現を調節するための組成物及び方法
FI3597749T3 (fi) 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
PT3363902T (pt) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
BR112018012744A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método de fabricação de um anel vaginal
KR20240027874A (ko) * 2016-07-28 2024-03-04 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도

Also Published As

Publication number Publication date
DK3491014T3 (da) 2023-05-30
SG11201900738YA (en) 2019-02-27
US10266582B2 (en) 2019-04-23
US20180030114A1 (en) 2018-02-01
KR20190034532A (ko) 2019-04-02
EP4230648A2 (en) 2023-08-23
EP3491014B1 (en) 2023-04-05
US10562953B2 (en) 2020-02-18
NZ751010A (en) 2024-11-29
US20200231651A1 (en) 2020-07-23
JP2023071704A (ja) 2023-05-23
IL264473A (en) 2019-02-28
CA3032124A1 (en) 2018-02-01
CN109563516B (zh) 2023-10-27
US20220073589A1 (en) 2022-03-10
JP2019527229A (ja) 2019-09-26
KR20240027874A (ko) 2024-03-04
WO2018022967A1 (en) 2018-02-01
EP3491014A1 (en) 2019-06-05
US11155598B2 (en) 2021-10-26
DK3491014T5 (da) 2024-09-02
CN109563516A (zh) 2019-04-02
US20190202891A1 (en) 2019-07-04
AU2017302611B2 (en) 2021-12-09
MX2024013403A (es) 2024-12-06
JP7556688B2 (ja) 2024-09-26
KR102661616B1 (ko) 2024-04-30
AU2017302611A1 (en) 2019-03-14
EP4230648A3 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2024013403A (es) Variantes de gpr156 y usos de estas
PH12019500596B1 (en) Recombinant binding proteins and their use
PH12019500209A1 (en) Methods and compositions for gene expression in plants
MX2019004810A (es) Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
EP4574992A3 (en) Combinatorial dna screening
CR20230026A (es) Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532)
HRP20231707T1 (hr) Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47
MX2017008670A (es) Moleculas artificiales de acido nucleico novedosas.
EA201691111A1 (ru) Химерные белки фактора viii и их применение
HRP20240855T1 (hr) Neljudske životinje koje imaju humanizirani gen cd274 iz diferencijacijske skupine
SG10201808565QA (en) Fgfr fusions
BR112015002280A2 (pt) produção de gado resistente a vfa por substituição de alelo
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
JP2019500414A5 (es)
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
SG10201901053TA (en) Novel tilapia virus and uses thereof
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112016017723A2 (pt) nucleotídeo de fitase de pteris vittata e sequências de aminoácido e métodos de uso
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
NZ752941A (en) Frataxin expression constructs
NZ729735A (en) Biosensor based on gβυ-interacting proteins to monitor g-protein activation
NZ724196A (en) Uti fusion proteins
CY1116486T1 (el) Βελτιωμενο συστημα εκφρασης ανθρωπινης μακρας πεντραξινης 3 και χρησεις αυτης
NZ762152A (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof